The "News Express" column aims to bridge the gap between cutting-edge research and clinical practice, allowing every hematology enthusiast and professional to quickly capture industry trends, spark innovative thinking, and broaden professional horizons. Hematology Frontier carefully selects the latest hematology research findings from top global journals, delivering every brilliant spark of science and clinical practice to you. We invite you to follow this column and join global hematology experts on the journey of scientific exploration!

Angioimmunoblastic T-cell lymphoma (AITL), as a major subtype of peripheral T-cell lymphoma (PTCL), poses significant challenges for clinicians due to its complex pathological features, variable clinical presentation, and poor prognosis. In recent years, with advances in medical research, novel diagnostic techniques and treatment methods for nTFHL have emerged, leading to new breakthroughs in diagnosis and therapy. However, patient outcomes remain bleak, underscoring the urgent need for further basic and clinical research to guide clinical practice and improve prognosis. Recently, Dr. Jianyong Li from Jiangsu Province Hospital provided a detailed overview of the latest research progress in nodal T-follicular helper cell lymphoma (nTFHL). Hematology Frontier has compiled these insights for our readers.

In the realm of cellular therapy, CAR-NK technology is spearheading a new wave of treatment possibilities. Given the current state of cellular therapy in China, advancing technologies like CAR-NK has become crucial. At the 12th Lu Daopei Hematology Forum, Hematology Frontier had the privilege of inviting Dr. Wenbin Qian from The Second Affiliated Hospital Zhejiang University School of Medicine to provide an in-depth analysis of the benefits and challenges of CAR-NK therapy, explore future research directions, and discuss new chapters in cellular therapy.

With the widespread adoption of chemotherapy-free treatment regimens and breakthroughs in targeted therapies, chronic lymphocytic leukemia (CLL) treatment has entered a new era. At the 12th Lu Daopei Hematology Forum, Hematology Frontier invited Dr. Shenmiao Yang from Peking University People’s Hospital to provide an in-depth analysis of the current state of CLL treatment in China, discuss future research directions, and explore new chapters in the development of the field.

Under the leadership of Dr. Jun Zhu, the Lymphoma Department at Peking Cancer Hospital has become a frontrunner in lymphoma drug development. This year, what innovative achievements from the team will illuminate the treatment path for lymphoma patients? How have they showcased Chinese expertise on the international stage? Additionally, how will the opportunities and challenges China faces in new drug development be transformed into driving forces to enhance lymphoma treatment standards? At the 12th Lu Daopei Hematology Forum, Hematology Frontier had the honor of conducting an in-depth interview with Dr. Jun Zhu. During the discussion, Professor Zhu not only reviewed the illustrious journey of China's lymphoma drug development but also, with his profound insights and forward-looking perspective, envisioned the limitless possibilities in this field's future. Let us delve into Professor Zhu’s remarkable analysis and unique insights on the development of lymphoma drugs in China.